Capital International, Inc. Ultragenyx Pharmaceutical Inc. Transaction History

Capital International, Inc.

$7.57 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $327,032 - $541,289	-8,184 Reduced 23.64%	26,429 $1.09 Million
Q2 2022 Aug 15, 2022	SELL	$45.8 - $85.4 $315,058 - $587,466	-6,879 Reduced 16.58%	34,613 $2.07 Million
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $3.62 Million - $4.91 Million	-58,206 Reduced 58.38%	41,492 $3.01 Million
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $18.6 Million - $22.1 Million	-251,801 Reduced 71.64%	99,698 $8.38 Million
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $3.72 Million - $4.88 Million	-47,682 Reduced 11.94%	351,499 $31.7 Million
Q2 2021 Aug 16, 2021	SELL	$92.19 - $115.71 $2.28 Million - $2.87 Million	-24,776 Reduced 5.84%	399,181 $38.1 Million
Q1 2021 May 14, 2021	SELL	$106.9 - $167.73 $6.62 Million - $10.4 Million	-61,909 Reduced 12.74%	423,957 $48.3 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $424,785 - $892,803	5,033 Added 1.05%	485,866 $67.3 Million
Q3 2020 Nov 13, 2020	BUY	$72.98 - $90.0 $217,115 - $267,750	2,975 Added 0.62%	480,833 $39.5 Million
Q2 2020 Aug 14, 2020	BUY	$46.91 - $78.22 $1.28 Million - $2.14 Million	27,363 Added 6.07%	477,858 $37.4 Million
Q1 2020 May 15, 2020	BUY	$33.8 - $62.9 $264,823 - $492,821	7,835 Added 1.77%	450,495 $20 Million
Q4 2019 Feb 18, 2020	SELL	$36.08 - $45.83 $1.02 Million - $1.3 Million	-28,405 Reduced 6.03%	442,660 $18.9 Million
Q3 2019 Nov 14, 2019	BUY	$42.5 - $63.11 $16.8 Million - $25 Million	396,300 Added 530.06%	471,065 $20.2 Million
Q2 2019 Aug 14, 2019	BUY	$54.93 - $74.36 $1.47 Million - $1.99 Million	26,715 Added 55.6%	74,765 $4.75 Million
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $163,825 - $285,000	4,109 Added 9.35%	48,050 $3.33 Million
Q4 2018 Feb 14, 2019	SELL	$38.89 - $77.3 $35,001 - $69,570	-900 Reduced 2.01%	43,941 $1.91 Million
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $775,619 - $973,710	10,801 Added 31.73%	44,841 $3.42 Million
Q2 2018 Aug 14, 2018	SELL	$48.54 - $85.31 $344,634 - $605,701	-7,100 Reduced 17.26%	34,040 $2.62 Million
Q1 2018 May 15, 2018	SELL	$44.33 - $58.52 $93,093 - $122,892	-2,100 Reduced 4.86%	41,140 $2.1 Million
Q4 2017 Feb 14, 2018	SELL	$43.54 - $57.32 $124,524 - $163,935	-2,860 Reduced 6.2%	43,240 $2.01 Million
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $2.3 Million - $3.06 Million	46,100	46,100 $2.46 Million

Others Institutions Holding RARE

# of Institutions

326

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

Vanguard Group Inc Valley Forge, PA

9.95M
Shares

$428 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$241 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.12M
Shares

$220 Million
0.91% of portfolio
Wellington Management Group LLP Boston, MA

4.17M
Shares

$179 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.07M
Shares

$132 Million
0.02% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.

Account